S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.84 (+0.06%)
DOW   39,728.06 (-0.08%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

$29.00
-0.24 (-0.82%)
(As of 10:21 AM ET)
Today's Range
$28.38
$29.29
50-Day Range
$26.15
$34.99
52-Week Range
$25.69
$77.14
Volume
30,943 shs
Average Volume
579,010 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.20

Omnicell MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
45.0% Upside
$42.20 Price Target
Short Interest
Bearish
4.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Omnicell in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
260.00%
From $0.10 to $0.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.35 out of 5 stars

Medical Sector

528th out of 939 stocks

Electronic Computers Industry

5th out of 6 stocks

OMCL stock logo

About Omnicell Stock (NASDAQ:OMCL)

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

OMCL Stock Price History

OMCL Stock News Headlines

Reasons for the Decline of Omnicell (OMCL)
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Omnicell Is Building A Strong Moat
OMCL Dec 2024 30.000 call
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Q4 2023 Omnicell Inc Earnings Call
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
Omnicell Q4 2023 Earnings Preview
Positive Report for Omnicell (OMCL) from Craig-Hallum
Wells Fargo Reaffirms Their Hold Rating on Omnicell (OMCL)
OMCL Aug 2024 40.000 put
OMCL Dec 2024 30.000 put
Omnicell initiated with bearish view at Barclays
BTIG Reaffirms Their Hold Rating on Omnicell (OMCL)
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/27/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electronic computers
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,650
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$42.20
High Stock Price Target
$75.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+44.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-20,370,000.00
Pretax Margin
-1.75%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Cash Flow
$3.24 per share
Book Value
$26.15 per share

Miscellaneous

Free Float
44,717,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.74

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


OMCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMCL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMCL, but not buy additional shares or sell existing shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price target for 2024?

6 Wall Street analysts have issued 12 month price targets for Omnicell's stock. Their OMCL share price targets range from $26.00 to $75.00. On average, they expect the company's stock price to reach $42.20 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2024?

Omnicell's stock was trading at $37.63 at the beginning of the year. Since then, OMCL stock has decreased by 22.6% and is now trading at $29.11.
View the best growth stocks for 2024 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings results on Thursday, February, 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. The company earned $258.85 million during the quarter, compared to analyst estimates of $256 million. Omnicell had a negative net margin of 1.78% and a positive trailing twelve-month return on equity of 3.43%.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of -0.100--0.100 for the period, compared to the consensus estimate of 0.310. The company issued revenue guidance of $232.0 million-$242.0 million, compared to the consensus revenue estimate of $262.4 million.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.25%), Vanguard Group Inc. (12.13%), Clearbridge Investments LLC (2.61%), Dimensional Fund Advisors LP (2.35%), Pacer Advisors Inc. (2.33%) and Geneva Capital Management LLC (2.06%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
This page (NASDAQ:OMCL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners